US 12,377,112 B2
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Derek John Londesbrough, Hartlepool (GB); Christopher Brown, Gateshead (GB); Julian Scott Northen, South Shields (GB); Gillian Moore, Sedgefield (GB); Hemant Kashinath Patil, Surrey (GB); David E. Nichols, Chapel Hill, NC (US); Hans Ake Eriksson, Altrincham (GB); George Goldsmith, Altrincham (GB); Ekaterina Malievskaia, Altrincham (GB); Manon Cecile Elisabeth Veraart, Altrincham (GB); Tobias Patrick Whelan, Altrincham (GB); and Lars Christian Wilde, Altrincham (GB)
Assigned to Compass Pathfinder Limited, Altrincham (GB)
Appl. No. 17/604,606
Filed by COMPASS PATHFINDER LIMITED, Altrincham (GB)
PCT Filed Apr. 17, 2020, PCT No. PCT/IB2020/053684
§ 371(c)(1), (2) Date Oct. 18, 2021,
PCT Pub. No. WO2020/212948, PCT Pub. Date Oct. 22, 2020.
Claims priority of provisional application 62/946,159, filed on Dec. 10, 2019.
Claims priority of provisional application 62/893,611, filed on Aug. 29, 2019.
Claims priority of provisional application 62/893,110, filed on Aug. 28, 2019.
Claims priority of provisional application 62/835,480, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,478, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,460, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,458, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,479, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,476, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,449, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,474, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,477, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,465, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,450, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,464, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,472, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,482, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,485, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,484, filed on Apr. 17, 2019.
Claims priority of provisional application 62/835,481, filed on Apr. 17, 2019.
Prior Publication US 2022/0169668 A1, Jun. 2, 2022
Int. Cl. A61K 31/675 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 31/661 (2006.01); A61P 25/00 (2006.01); A61P 25/04 (2006.01); A61P 25/08 (2006.01); A61P 25/16 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); C07F 9/572 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/48 (2013.01); A61K 31/661 (2013.01); A61P 25/00 (2018.01); A61P 25/04 (2018.01); A61P 25/08 (2018.01); A61P 25/16 (2018.01); A61P 25/20 (2018.01); A61P 25/22 (2018.01); A61P 25/24 (2018.01); A61P 25/28 (2018.01); C07F 9/5728 (2013.01); C07B 2200/13 (2013.01)] 27 Claims
 
1. A method for treating attention-deficit hyperactivity (ADHD) disorder in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of crystalline psilocybin, wherein the crystalline psilocybin is characterized by XRPD peaks at 11.5±0.1, 12.0±0.1, 14.5±0.1, 17.5±0.1 and 19.7±0.1° 2θ, and wherein the crystalline psilocybin has a chemical purity of greater than 97% as determined by HPLC analysis.